Li Wei, Zhou Zhichao, Zheng Jie. Trends and hotspots in multidrug-resistant tuberculosis research in China (1995—2023)[J]. Chinese Journal of Antituberculosis, 2025, 47(6): 785-791. doi: 10.19982/j.issn.1000-6621.20250112
World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[3]
Campbell JR, Brode SK, Barry P, et al. Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis. Thorax, 2024, 79(2):169-178. doi:10.1136/thorax-2023-220249.
pmid: 38135489
[4]
Zhou G, Luo S, He J, et al. Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect, 2024, 30(2):189-196. doi:10.1016/j.cmi.2023.09.015.